Chemokine (C-C motif) ligand 2 (CCL2), a candidate of cytokines, orchestrates immune cell recruitment to inflamed organs. CCL2 has been shown to have direct angiogenic effects, so providing an anti-angiogenic agent, Avastin (AV), to be combined with the CCR2 antagonist (concentration ratio [CR]) plays an essential role in the hemostatic strategy for immunomodulation. Lack of targetability and the adverse effects of chemical treatments are the main obstacles led scientists to develop novel strategies using nano-delivery approaches such as pegylated nanoparticles (NPs) which exhibits reduced drug clearance rates. The rationale of the current study is to test the in vivo immunomodulatory effects of AV and/or CR in their NPs or free counterparts.

**Methods:** These NPs were synthesized and characterized using different physicochemical techniques. Males Wistar rats (n=114) were used and divided into 7 groups treated with vehicle, AV, AVNP, CCR2 antagonist (CR), CCR2 antagonist NPs (CRNP), AV-CCR2 antagonist (AVCR), and AV-CCR2 antagonist NPs (AVCRNP). Groups were subdivided into three subgroups according to the administrated dose. Blood was taken from rats for differential leukocyte and platelet profile measurements. Sera were collected to test vascular endothelial growth factor (VEGF) levels. Autopsy samples from liver were taken for histopathological investigation.

**Results:** The morphology of the NPs was spherical and had sizes ranging from 89.89 nm to 146 nm. Monocytes and lymphocytes accumulated in the blood circulation and VEGF levels were inhibited after AV and CR administrations. In addition, large platelets concentration ratio was elevated in the blood circulation.

**Conclusion:** We concluded that AV ad CR therapeutic regimens have an immunomodulatory role through induction of monocyte-platelet aggregation and inhibition of VEGF.

**Keywords:** Immunomodulation, Avastin, CCR2 antagonist, Monocyte-platelet connection, Vascular endothelial growth factor.
Lack of targetability and instability in addition to adverse effects of chemical-based treatments are the main obstacles led scientists to develop novel strategies to tackle diseases using nano-delivery approaches [17–21]. Recently, several delivery systems were developed by utilizing pegylated products [22]. These procedures augmented the half-life and bostle of drugs, and diminished liver toxicity [23].

Overall, the rationale of the current study is to test the immunomodulatory effects of the anti-VEGF AV and/or CCR2 antagonist (CR) in their pegylated nanof ormulation or free counter parts, understanding the mechanisms modulating immunity in rats to get closer to suggest some further recommendations regarding angiogenesis-mediated immunomodulation through targeting liver microenvironment which may gain great success in cancer eradication in near future.

MATERIALS AND METHODS

Materials

Methoxy polyethylene glycolamine (mPEG-NH₂, MW: 5000 Da), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide (NHS), heparin (HP), PEG (MW 5000 Da), 2-(N-morpholino)ethanesulfonic acid (MES), dimethyl sulfoxide, Tween 80, and poly L-lysine (PLL), and CCR2 antagonist RS 504393 (CR) were purchased from Sigma-Aldrich, USA. Bevacizumab AV was purchased from Genentech Inc., USA. Ultrapure water (Millipore, Bedford, MA, USA) was used.

Preparation of AV and CR nanoparticles (NPs)

Nano-void (NV) synthesis

According to a previous method mentioned in Lim et al. [24], we used it with some modifications to preparePEG-exposed NPs (NV). To prepare NV, we first prepared the mixture of EDC and NHS. Briefly, HP (HP: 0.1 mM) was coupled with 0.1 mM of mPEG-NH₂ (MW 5000 Da) using EDC (1.5 mM) and NHS (1.6 mM) in MES buffer (pH 5.5) at room temperature for 24 h stirring. Then, NV was prepared simply by mixing the polymer (PEG-HP) with PLL buffer (6:1 v/v ratio) overnight at 4°C.

AVNPs synthesis

To prepare the PEG-NPs of bevacizumab AV monoclonal antibody (AV NPs); first, the PEG-HP polymer was synthesized as above and the CRNPs were prepared by mixing the polymer with PLL buffer (6:1 v/v ratio) overnight at 4°C.

AVNPs characterization

Dialysis technique and measurement of the encapsulation efficiency

All nano-samples were divided into two portions; (1) one for measuring the total concentrations of the free plus nano-conjugated AV and CR and (2) the second part for measuring the concentrations of the nano-conjugated AV and CR after performing dialysis tubing technique for eliminating the impurities and the free drug using a membrane bag (Spectra/Por Membrane, Spectrum Laboratories, USA; molecular weight cut-off, MWCO: 25,000 Da).

The free and conjugated forms of AV and CCR2 antagonist were detected with a variable wavelength detector using a UV-based ELISA system. The calibration curves for quantification of these compounds were linear over the range of standard concentrations. Finally, encapsulating (entrapment) efficiency (EE) was calculated after dialysis technology.

Transmission electron microscopic (TEM)

Particle morphology of all NPs was examined by TEM (TEM, Philips CM-10, FEI Inc., Hillsboro, OR, USA). 100 µg/ml of the nano-suspensions were dropped into formvar-coated copper grids, and after complete drying, the samples were stained using 2% w/v Uranyl Acetate (Electron Microscopy Services, Ft. Washington, PA). Image capture and analysis were done using Digital Micrograph and Soft Imaging Viewer Software.

Particle size distribution and zeta potential

The particle size and zeta potential analyses of all NPs were performed by photon correlation spectroscopy (PCS) and laser diffractometry (LD). For PCS measurements, 1 mL of the NPs solution was filled in the disposable transparent sizing clear cuvette, and the size of the sample was analyzed at 25°C with a Malvern Zetasizer (Malvern Instruments, Westborough, Massachusetts). All measurements were performed in triplicate.

Fourier transform infrared spectroscopy (FTIR)

FTIR spectra of PEG-amine, HP, PLL, MES, NVNPs, AVNPs, CRNPs, and AV-CR NPs were determined using Bruker Vector 22 FTIR. The spectra were obtained in the range of 500–4000 cm⁻¹.

In vivo application

Animals

A total of 114 (n=114) male Albino rats of Wistar strain (body weight 100–120 g) were used in this study. Animals will be obtained from the Animal House Colony at National Research Centre, Giza, Egypt. The animals were housed in a specific pathogen-free barrier area in a room with controlled temperature (22±1°C) and humidity (50±10%) and a 12 h light/dark cycle. The rats were allowed ad libitum access to water and standard laboratory diet consisting of casein 10%, salts mixture 4%, vitamins mixture 1%, corn oil 10%, and cellulose 5% completed to 100 g with cornstarch [25]. The study protocol followed the guidelines approved by the ethical Committee of the Medical Research of the National Research Centre (Approval No. 16/281).

Experimental design

A total of 114 males (n=114) of Wistar rats were used in the current study and divided into 7 groups. All groups were treated daily for 30 days with vehicle (Group 1, control, n=6), AV (Group 2, n=18), AVNP (Group 3, n=18), CR (Group 4, n=18), CRNP (Group 5, n=18), AVCR (Group 6, n=18), and AVCRNP (Group 7, n=18). Groups (2–7) were subdivided into three subgroups (n=6 in each subgroup) according to the administrated dose (high safe dose, D1; half safe dose, D2; and quarter safe dose, D3). These doses (showed in Table 1) were administrated orally and determined according to a preliminary study that was performed about acute and chronic toxicity of these nano-formulations in vivo.

Blood sampling and biochemical investigations

At the end of the experimental period, rats were fasted overnight and subjected to diethyl ether anesthesia. Blood samples were
From sampling to differential leukocytes and platelets measurement
Medonic M32 analyzer included MPA micro-pipette adapter for sampling (Boule Diagnostics AB Company, Sweden) was used for complete blood count (CBC) of rat blood samples which collected using vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) (BD Company, Canada) for differential leukocytes and platelets, while the second portion was kept to clot in clean, dry test tubes, and then centrifuged at 1,800 g for 10 min to obtain sera. The clear supernatant sera were used for VEGF concentration measurements.

VEGF level measurement using ELISA
Rat VEGF ELISA Kit (Cat. No. E-EL-R0020, Elabscience Biotechnology Co., USA) was used for quantitative determination of rat VEGF concentrations in rat sera after the different treatments compared to control. The principle of this kit is based on the sandwich-ELISA method. Briefly, we have drawn a standard curve using the provided VEGF standard. The standard working solution was prepared by centrifuging the standard at 10,000 g for 1 min. Then, 1 mL of the provided reference standard and sample diluent was added and left for 10 min by mixing gently. The reconstitution produced a working solution of 2000 pg/mL, then we made serial dilutions as follows: 2000, 1000, 500, 250, 125, 62.5, 31.25, and 0 pg/mL. We started the procedure for 10 min earlier before adding 100 µL of it to each well; then the plate was incubated for 30 min at 37°C, thereafter the liquid was removed. We diluted the biotinylated detection Ab (1: 100) and left it for 15 min earlier before adding 100 µL of it to each well; then the plate was incubated for 1 h at 37°C. The plate was aspirated and washed for 3 times. We diluted the concentrated horseradish peroxidase (HRP) conjugate (1: 100) and left it for 15 min earlier before adding 100 µL of HRP conjugate to each well; then the plate was incubated for 30 min at 37°C. The plate was aspirated and washed for 3 times. 50 µL of the provided substrate reagent was added and incubated for 15 min at 37°C. The reaction in each well was stopped before reading by 50 µL of stop solution, then the OD value at 450 nm was determined immediately. The OD is proportional to the concentration of rat VEGF. The concentration of rat VEGF was calculated in the samples by comparing the OD of the samples to the diagrammed standard curve.

Table 1: The doses of the administered therapeutic regimens

| Groups | Mg/kg |
|--------|-------|
|        | High safe dose, D1 | Half safe dose, D2 | Quarter safe dose, D3 |
| AV     | 5      | 2.5            | 1.25            |
| AVNP   | 5      | 2.5            | 1.25            |
| CR     | 0.001  | 0.0005         | 0.00025         |
| CRNP   | 0.001  | 0.0005         | 0.00025         |
| AVCR   | 5+0.001| 2.5+0.0005     | 1.25+0.00025    |
| AVCRNP | 5+0.001| 2.5+0.0005     | 1.25+0.00025    |

From tissue sampling to histopathological investigation
Autopsy samples were taken from the liver of rats in the different groups and fixed in 10% formol saline for 24 h. Washing of samples was done in tap water then serial dilutions of alcohol (methyl, ethyl, and absolute ethyl) were used for dehydration. Specimens were cleared in xylene and embedded in paraffin at 56°C in hot air oven for 24 h. Paraffin bees wax tissue blocks were prepared for sectioning at 4 microns thickness by sledge microtome. The obtained tissue sections were collected on glass slides, deparaffinized, and stained by hematoxylin and eosin stains for examination through the light electric microscope [26].

RESULTS AND DISCUSSION
Characterization of NPs

EE
For measuring the EE of AV in the nano-capsules (AVNPs and AV-CRNPs), calibration curve of AV after dialysis tubing was performed. The serial dilutions used for drawing the calibration curves are 0.39, 0.78, 1.56, and 3.12 mg/mL as shown in Fig. 1. The EE of AV in AV NPs was 86 ± 5.5 and in AV-CRNPs was 82 ± 7.0.

For measuring the EE of CCR2 antagonist (CR) in the nano-capsules (CRNPs and AV-CRNPs), calibration curve after dialysis tubing was performed. The serial dilutions used for drawing the calibration curve are 0.0078, 0.0156, 0.0312, 0.0625, and 0.125 mg/mL as shown in Fig. 1. The EE of CR in CR NPs was 74 ± 2.8 and in AV-CR NPs was 75 ± 6.4.

TEM
TEM was used for imaging of PEG-based NPs as illustrated in Fig. 2. The morphology of the NV is spherical in shape as illustrated in Fig. 2a. In addition, these spherical NVNPs have sizes ranging from 89.89 nm to 99.06 nm as illustrated in Fig. 2b. In Fig. 2c, high scale field (1 µm) of AV NPs morphology shows spherical core particles surrounded by monoclonal AV antibody. Sizes of AV NPs were in the range of 145–146 nm. In Fig. 2d, high scale field (500 nm) of CRNPs morphology shows that spherical particles were illustrated. Sizes of CRNPs were in the range of 57.7–73.3 nm.

Fig. 2e shows TEM images of AVCR NPs. It illustrates high scale field (500 nm) of AV-CRNPs morphology shows spherical core particles surrounded by monoclonal AV antibody. Sizes of AVNPs were in the range of 139–155.65 nm.

Size and zeta potential stability of NPs
As shown in Fig. 3, size distribution and apparent zeta potential of the NPs were characterized. Representative size distribution (108.9 nm) of AV was drawn using Malvern Zetasizer system based on PCS and LD as illustrated in Fig. 3a. In addition, representative zeta potential (4.99 mV) of NV was drawn using Malvern Zetasizer system based on PCS and LD as illustrated in Fig. 3b. Representative size distribution (147.8 nm) of AVNPs was drawn in Fig. 3c. Representative zeta potential (−9.05 mV) of AVNPs was drawn in Fig. 3d. Representative size distribution (76.26 nm) of CR NPs was drawn in Fig. 3e. Representative zeta potential (−2.81 mV) of AVNPs was drawn in Fig. 3f. Representative size distribution (293.4 nm) of AV-CRNPs was drawn in Fig. 3g. Representative zeta potential (4.71 mV) of AV-CRNPs was drawn in Fig. 3h.

FTIR spectroscopy
Schematic diagram (Fig. 4) of NPs was illustrated to figure the vehicle components that incorporated in the nano-encapsulation of all particles. To prepare PEG NPs, we first prepared the mixture of EDC and NHS. Then, PEG NPs were characterized. Representative size distribution (108.9 nm) of NV was drawn using Malvern Zetasizer system based on PCS and LD as illustrated in Fig. 3a. In addition, representative zeta potential (4.99 mV) of NV was drawn using Malvern Zetasizer system based on PCS and LD as illustrated in Fig. 3b. Representative size distribution (147.8 nm) of AVNPs was drawn in Fig. 3c. Representative zeta potential (−9.05 mV) of AVNPs was drawn in Fig. 3d. Representative size distribution (76.26 nm) of CR NPs was drawn in Fig. 3e. Representative zeta potential (−2.81 mV) of AVNPs was drawn in Fig. 3f. Representative size distribution (293.4 nm) of AV-CRNPs was drawn in Fig. 3g. Representative zeta potential (4.71 mV) of AV-CRNPs was drawn in Fig. 3h.
Fig. 1: Calibration curves of Avastin (AV) and CCR2 antagonist (CR) used for measuring entrapment efficiency of AV nanoparticles (NPs), CRNPs, and AV-CRNP.

Fig. 2: Transmission electron microscopic analyses. (a) NV morphology was spherical in shape. (b) Sizes of spherical NV nanoparticles (NPs) were 89.89 nm and 99.06 nm. (c) AVNPs morphology shows spherical core particles surrounded by monoclonal AV antibody. Sizes of AVNPs were in the range of 145–146 nm. (d) CRNPs morphology shows spherical particles. Sizes of CRNPs were in the range of 57.7–73.36 nm. (e) AV-CRNPs morphology shows spherical core particles surrounded by monoclonal AV antibody. Sizes of AVNPs were in the range of 139–155.65 nm.

which were determined using Bruker Vector 22 FTIR. The spectra were obtained in the range of 500–4000 cm⁻¹. NV encapsulation is accompanied with amide bond "O=C-NH" formation. On the other hand, NV encapsulation is accompanied with amide bond "O=C-NH" formation. On the other hand, AVNPs were determined using Bruker Vector 22 FTIR. The spectra were obtained in the range of 500–4000 cm⁻¹. NV encapsulation is accompanied with peptide bond "O=C-NH" formation. Fig. 5a. 5b shows the FTIR of HP and PLL which were magnified to increase clarity. Moreover, FTIR of NV NPs, AV, and AV NPs were determined using Bruker Vector 22 FTIR Fig. 6a. The spectra were obtained in the range of 500–4000 cm⁻¹. NV encapsulation is accompanied with amide bond "O=C-NH" formation. Fig. 6b illustrates the FTIR of NVNPs, AV, CR, CRNPs, and AV-CRNP which were determined. Fig. 6c illustrates the FTIR of AV and CR which were magnified to increase clarity.

Immunomodulation: Immune cells, platelets, and VEGF network
AV, AVNP, CR, CRNP, ACHR, and ACHRNP played a crucial role in immunomodulation after their administration in vivo rats. In Fig. 7a, monocytes were high significantly (p<0.01) elevated in blood after treatments with AV, AVNP, CR, CRNP, ACHR, and ACHRNP. This elevation of monocytes led to an accumulation of these immune cells in the circulatory system. This elevation of monocytes led to an accumulation of these immune cells in the circulatory system. We noticed that there was a significant dose-dependent increase (p<0.05) in the nanoformalized regimens of AV, CR, and ACHR, while there was no stable pattern in the case of the free regimens of AV, CR, and ACHR. In addition, lymphocytes were significantly (p<0.05) elevated in blood after treatments with AV, AVNP, CR, CRNP, ACHR, and ACHRNP as shown in Fig. 7b. This elevation of lymphocytes led to an accumulation of these immune cells in the circulatory system. We noticed that there was a significant dose-dependent increase (p<0.05) of lymphocytes only in the individual regimens including AV, AVNP, CR, and CRNP, while there was a significant dose-dependent decrease (p<0.05) only in the combinatorial regimens including ACHR and ACHRNP. However, 0.0005 mg/kg of CRNP (the quarter dose) induced the elevation of lymphocytes more than 0.00025 mg/kg of CRNP (the half dose), we observed a strange pattern in the case of CRNP, where the lymphocytes after the high dose of CRNP (0.001 mg/kg) administration was significantly decreased (p<0.001) compared to the half and the quarter doses and even the control.

Furthermore, there were total leukocyte (WBCs) and granulocyte patterns of dose-dependent decreases (p<0.05) after treatments with AV, AVNP, CR, CRNP, ACHR, and ACHRNP as shown in Table 2.

Fig. 7c and d showed the haemostatic balance between platelets and the LP (the LPCR), where the platelets were decreased significantly (p<0.05) in blood (Fig. 7c), while the LPCR was elevated in the blood circulation (Fig. 7d). Table 3 showed that there were no dramatically changes of MPV, PDW, and PCT levels in the blood circulation when comparing the treated groups of the administrated therapeutic regimens with the control.

Fig. 7e illustrated that VEGF levels in rat sera were significantly decreased (p<0.01) when comparing the treated groups with the control. We noticed that there was a significant dose-dependent increase (p<0.05) of VEGF levels only in the individual regimens including AV, AVNP, CR, and CRNP, while there was a significant dose-dependent decrease (p<0.05) only in the combinatorial regimens including ACHR and ACHRNP.
Abd-Rabou et al.

Fig. 4: Schematic diagram of nanoparticles encapsulation. To prepare PEG-HP- poly L-lysine (PLL) NPs, we first prepared the mixture of EDC and NHS. Then, NPs were produced by mixing the polymer with PLL phosphate buffer overnight at 4°C. The mix ratio (1:6 v/v, PLL: PEG-HP). NV, AVNPs, CRNPs, and AV-CRNPs encapsulation is accompanied with peptide bond “O=C-NH” formation.

Histopathological alterations
The obtained tissue sections taken from the rat liver were stained by hematoxylin and eosin stains for investigation through the light electric microscope. Histopathological alterations were shown in Fig. 8. In control liver, there was no histopathological change, and the normal histological structure of the central vein and hepatocytes in the parenchyma were
recorded as shown in Fig. 8a. After AV administration with the high dose, the parenchyma showed focal necrosis with inflammatory cells infiltration associated with congestion in the central vein as well as the portal vein as shown in Fig. 8b. After AV administration with the quarter dose, focal necrosis with inflammatory cells infiltration was detected in the parenchyma associated with edema and inflammatory cells infiltration in the portal area as shown in Fig. 8c. After AVNP administration with the high dose, the portal area showed inflammatory cells infiltration, while the parenchyma had focal necrosis as shown in Fig. 8d. After AVNP administration with the quarter dose, the parenchyma showed focal necrosis associated with inflammatory cells infiltration in the portal area as shown in Fig. 8e. After CRNP administration with the high dose, massive inflammatory cells infiltration was detected in the portal area as shown in Fig. 8f. After CR administration with the high dose, massive inflammatory cells infiltration was detected in the portal area as shown in Fig. 8g. After CRNP administration with the high dose, periductal fibrosis with inflammatory cells infiltration was detected surrounding the bile ducts at the portal area with congestion in the portal vein as shown in Fig. 8h. After CRNP administration with the quarter dose, the portal area showed focal inflammatory cells aggregation as well as diffuses inflammatory cells infiltration in the others with congestion in the portal vein as shown in Fig. 8i. After CRNP administration with the high dose, massive inflammatory cells infiltration was detected surrounding the bile ducts at the portal area with congestion in the portal vein as shown in Fig. 8h. After CRNP administration with the quarter dose, the portal area showed massive inflammatory cells infiltration as well as focal inflammatory cells aggregation in the parenchyma as shown in Fig. 8i. After AVCRNP administration with the high dose, massive inflammatory cells infiltration was detected in the portal area as shown in Fig. 8j.

Leukocyte migration process involves multi-steps and regulates the presence of immune cells throughout the human being’s body. In normal noninflammatory circumstances, homeostatic chemokines are supposed to adjust the transmission of hematopoietic cells intermediate - between blood and tissues. Inflammation induces changes in the cellular compositions of these sites, with quicker infiltration of immune cells from the bone marrow to the circulation [27].

The infiltration of the circulating immune cells into tissues is supposed to be driven by connections between chemokine receptors (example: CCR2)
Fig. 7: The mechanism of the action of immunomodulation after AV, AVNP, CR, CRNP, AVCR, and AVCRNP administrations in vivo. Monocytes (a) and lymphocytes (b) were significantly accumulated in blood after treatments with AV, AVNP, CR, CRNP, AVCR, and AVCRNP. Platelets were decreased in blood (c), while the LP (the LPCR) was elevated in the blood circulation (d). (e) VEGF levels in rat sera were significantly decreased when comparing the treated groups with the control. (f and g) Schematic diagrams of the mechanism of action of immunomodulation after AV and CR regimens administrations in rats (g) compared to the control (f).
and their ligands (example: CCL2) [28]. CCR2 has been allied with the recruitment of monocytes and/or lymphocytes from the circulation to the target sites [29,30]. Herein, we have examined the effect of CCR2 antagonist on monocyte and lymphocytes relocation. Our results have designated that CCR2-CCR2 antagonist interactions were blocked the infiltration of monocytes from the blood, resulting in an accumulation of these types of immune cells in the circulation, as we observed in the results (Fig 7g). This observation is in agreement with a previous study [31]. For more clarification of that point, it was validated that the lack of CCR2 changed the shape of circulating monocytes recommending that reduced inflammation may consequence from diminished inflammatory monocyte rate in the circulation rather than from reduced staffing of monocytes from the circulation into tissues [31]. Monocyte relocation from the circulation to the organ and succeeding relocation toward T cell parts of the white pulp might encompass the consecutive arrangement of numerous chemokines separate from CCR2 [32,33].

Basically, CCL2 is secreted in response to inflammation [34]. In normal conditions, low secretion of CCL2 persuades CCL2 secretion in the spleen and the blood circulation [35].

A considerable number of clinical surveys emphasized that inflammation contributes greatly in tumor formation [36]. The crosstalk between tumor cells and the tumor-infiltrating cells is also shown recently as a significant contributor in cancer development, drug resistance, and cancer invasion. For example, CCL2, secreted by numerous tumors, mediates immunoinhibitory effects and facilitates tumor metastasis. Blocking of CCL2-CCR2 signaling using CCR2 antagonist, as studied here in the current study, can be further used to boost CD8+ T-cell-mediated responses and inhibit metastasis [37]. However, even though angiogenesis is the communal leading cause of tumor progression, abruptly targeting the crucial contributing factor, VEGF, is still risky. Based on the assumption that tumor mass consists of multigenotypic population, the VEGF-targeting therapy (i.e. AV) may select for the adapting tumor cells [38]. According to previous results from human cancer studies, anti-VEGF therapy usually results in regrowth of clonal populations with the characteristics of expressing higher compensatory factors such as VEGF, fibroblast growth factor, and platelet-derived growth factor [38], so we used AV in combination with CCR2 antagonist (CR) to inhibit VEGF and block the CCR2-CCL2 signaling network that may be used as a promising anticancer therapeutic regimen in further studies.

It was suggested that nano-formulation of chemotherapies increases their targetability and stability in addition to reduces adverse effects of them and provides adequate drug delivery approach [18-21]. Recently, several delivery systems were developed by utilizing pegylation process [39], which increased the half-life and activity of drugs, and reduced liver toxicity in mice, thus allowing the drug dosages to be reduced [40]. NPs have been great predestined as carriers for the delivery of drugs due to their small size, and sustained-release characteristics [41,42].

In the current study, we used PEG and PLL for synthesizing the AV, CR, and AV-CR NPs. PLL has a benefit of being hydrodegradable, biodegradable, and biocompatible [43], and so it is appropriate for the backbone as a drug delivery transporter. Recently, it has been reported that PLL-modified poly (lactic-co-glycolic acid) (PLGA) NPs presented significantly higher quantities than unmodified PLGA NPs [44]. Therefore, in this work, we selected PLL and PEG for encapsulating AV and CCR2 antagonist (CR) to achieve bioavailable and biocompatible NPs as well as the sustained release of these drugs.

Our AV PEG-PLL NPs noted high encapsulation efficiency (EE >86%) of AV with high stability based on the zeta potential negative charges (−9.05±1.2) reported on the surface of the synthesized AVNPs, then TEM images came to confirm its uniformity and z-average diameter came to confirm that it is in the nano-range (147±3.4) and PDI of 0.01. On the contrary, the authors in a previous study [45] found that a higher loading of AV, the PLGA particles lost its uniform, this was most likely due to fractional phase parting of PLGA polymer and AV. It was suggested that nano-formulation of chemotherapies increases their targetability and stability in addition to reduces adverse effects of them and provides adequate drug delivery approach [18-21]. Recently, several delivery systems were developed by utilizing pegylation process [39], which increased the half-life and activity of drugs, and reduced liver toxicity in mice, thus allowing the drug dosages to be reduced [40]. NPs have been great predestined as carriers for the delivery of drugs due to their small size, and sustained-release characteristics [41,42].

In the current study, we used PEG and PLL for synthesizing the AV, CR, and AV-CR NPs. PLL has a benefit of being hydrodegradable, biodegradable, and biocompatible [43], and so it is appropriate for the backbone as a drug delivery transporter. Recently, it has been reported that PLL-modified poly (lactic-co-glycolic acid) (PLGA) NPs presented significantly higher quantities than unmodified PLGA NPs [44]. Therefore, in this work, we selected PLL and PEG for encapsulating AV and CCR2 antagonist (CR) to achieve bioavailable and biocompatible NPs as well as the sustained release of these drugs.

Table 2: WBCs and granulocytes measurements after the dose-dependent manner of the administrated therapeutic regimens

| Parameters | Groups | CT | D1 | D2 | D3 |
|------------|--------|----|----|----|----|
| WBCs       | AV     | 11.8±1.01 | 7.4±0.62 | 9.0±0.75 | 6.3±0.57 |
|            | AVNP   | 11.8±1.01 | 8.8±0.73 | 11.4±0.95 | 5.7±0.52 |
|            | CR     | 11.8±1.01 | 9.5±0.79 | 11.2±0.93 | 11.3±1.03 |
|            | CRNP   | 11.8±1.01 | 6.9±0.58 | 14.2±1.18 | 23.5±2.14 |
|            | AVCR   | 11.8±1.01 | 7.6±0.63 | 11.4±0.95 | 13.0±1.18 |
|            | AVCRNP | 11.8±1.01 | 8.8±0.73 | 7.8±0.65 | 10.6±0.96 |
| Granulocytes (%) | AV | 33.1±2.83 | 16.3±1.36 | 19.5±1.63 | 11.7±1.06 |
|            | AVNP   | 33.1±2.83 | 17.8±1.48 | 17.4±1.45 | 16.3±1.48 |
|            | CR     | 33.1±2.83 | 20.8±1.73 | 21.3±1.78 | 10.8±0.98 |
|            | CRNP   | 33.1±2.83 | 20±1.67 | 26.8±2.23 | 57.2±5.20 |
|            | AVCR   | 33.1±2.83 | 11.4±0.95 | 15.5±1.29 | 40.3±3.66 |
|            | AVCRNP | 33.1±2.83 | 15.4±1.28 | 15.6±1.30 | 20.7±1.88 |

Table 3: MPV, PDW, and PCT measurements after the dose-dependent manner of the administrated therapeutic regimens

| Parameters | Groups | CT | D1 | D2 | D3 |
|------------|--------|----|----|----|----|
| MPV        | AV     | 5.7±0.49 | 5.1±0.51 | 5.6±0.47 | 5.9±0.54 |
|            | AVNP   | 5.7±0.49 | 5.7±0.48 | 6.5±0.54 | 6.6±0.60 |
|            | CR     | 5.7±0.49 | 6.8±0.57 | 6.5±0.54 | 6.6±0.60 |
|            | CRNP   | 5.7±0.49 | 5.7±0.48 | 5.5±0.46 | 6.1±0.55 |
|            | AVCR   | 5.7±0.49 | 6.3±0.53 | 6.1±0.51 | 6.1±0.55 |
|            | AVCRNP | 5.7±0.49 | 6.7±0.56 | 6.3±0.53 | 6.3±0.57 |
| PDW        | AV     | 8.8±0.75 | 6.2±0.52 | 8.6±0.72 | 9.1±0.83 |
|            | AVNP   | 8.8±0.75 | 8.0±0.73 | 9.8±0.82 | 9.9±0.90 |
|            | CR     | 8.8±0.75 | 10.6±0.83 | 9.8±0.82 | 9.9±0.90 |
|            | CRNP   | 8.8±0.75 | 8.7±0.73 | 8.6±0.72 | 9.1±0.83 |
|            | AVCR   | 8.8±0.75 | 9.4±0.78 | 9.3±0.76 | 9.2±0.84 |
|            | AVCRNP | 8.8±0.75 | 9.9±0.83 | 9.4±0.78 | 9.5±0.86 |
| PCT        | AV     | 0.54±0.05 | 0.38±0.03 | 0.34±0.03 | 0.23±0.02 |
|            | AVNP   | 0.54±0.05 | 0.34±0.03 | 0.42±0.04 | 0.42±0.04 |
|            | CR     | 0.54±0.05 | 0.62±0.05 | 0.28±0.02 | 0.37±0.03 |
|            | CRNP   | 0.54±0.05 | 0.21±0.02 | 0.42±0.04 | 0.53±0.05 |
|            | AVCR   | 0.54±0.05 | 0.31±0.03 | 0.39±0.03 | 0.30±0.03 |
|            | AVCRNP | 0.54±0.05 | 0.54±0.05 | 0.60±0.05 | 0.63±0.06 |
In a previous study, PEG-grafted chitosan NPs were synthesized [49]. PEG-PLL NPs. PLGA instigated degrading and released additional drug entrapped in double emulsion method [45]. However, in our study, drug EE was only about 45%. Hao et al. [47] also conveyed a similar result of our PEG-PLL based NPs. Unlike PLGA, the hydrophilicity of PEG also facilitated dispensing the particles [45]. These results are in agreement of four PEG-PLL based NPs.

It is suggested that the use of liposomes was stated for augmenting the in vivo residence of AV in in vivo model [46]. However, the described drug EE was only about 45%. Hao et al. [47] also conveyed a similar drug EE using ethyl acetate and phosphate solution. However, in our method, the EE of the AV PEG-PLL NPs recorded (86%), which is a bit similar to Li’s PLGA-PEG drug EE (90%), which was achieved through double emulsion method [45].

The problem of AV PLGA NPs is that after a certain time period, the PLGA instigated degrading and released additional drug entrapped in the polymeric base [48], so it is not stable such as our synthesized AV PEG-PLL NPs.

In a previous study, PEG-grafted chitosan NPs were synthesized [49]. As FTIR technique was investigated in the current study, they also performed the same techniques and indicated that the nonexistence of peaks at 1774 cm⁻¹ and 1710 cm⁻¹ in their NPs confirm the complete dissociation of phthalimido group from chitosan and the entrance of peaks 1633 cm⁻¹ (amide I) and 1582 cm⁻¹ (amide II) corresponds to the attendance of primary amine groups in chitosan. The peak at 2871 cm⁻¹ refers to the attendance of PEG, which a little bit similar to our FTIR results.

CCL2 was proved to recruit the monocytes into the area of dynamic inflammation. In this term, it was found that the inspiration of RANTES leads to staffing of monocytes/lymphocytes [50,51]. Apart from employing leukocyte movement, many lines of signals indicate that CCL2 might affect T-immunity. First, CCL2 upregulation is linked with the progress of polarized Th1 responses [52], and CCL2 improves the emission of IL-4 by T cells [53]. Second, in Th, immune-mediated diseases, such as asthma, CCL2 is expressed at high levels, and its neutralization in animal models ameliorates disease [54]. Finally, other chemokines and their receptors are linked to specific responses of T-helper cells [55]. These findings provide an important clue in the current study as to why when we blocked the CCR2-CCL2 signaling pathway the monocytes and lymphocytes were not infiltrated and then accumulated in the circulation.

This may be critical for the effective directive of the immune reply to cancer and viral infection for further studies. For example, Th and Th cells, due to their dissimilar chemokiner receptor expression design induced by CCL2, are likely to have dissimilar susceptibility to viral infection [53].

Chemokines are elaborate in normal activities in the host that affect tumor; hence, it is probable that they will be existing to have important impacts on different cancers. For this reason, chemokines might be predictable to have growth regulating effects on cancer cells depending on the specific setting in which they are found. Further, due to their ability to attract lymphocytes, some chemokines might be predicted to activate host antitumor replies. On the other hand, certain chemokines are known to have angiogenic properties, which could relate to tumor progression [56]. CCL2 expression in tumor cells is significantly connected with the extent of tumor-associated-macrophage (TAM) penetration [57], and in particular, both CCL2 and VEGF expressions were positively linked with TAM infiltration, angiogenesis, and then poor cancer survival [58].

The observations presented in a previous study [59] indicated that activated platelet interactions with the monocytes promote the inducible form of cyclooxygenase (COX-2) expression and augmented prostaglandin E2 (PGE2) synthesis by monocytes by methods concerning cellular adhesion and in response induced cytokine pathways. Rapid binding of P-select in on the plasma membranes of triggered platelets to the monocytes mediates stable communication between the 2 cell types [60]. Moreover, monocytes adhesion to P-select modulates the protein and gene expression of COX-2. A similar design was described for some transcripts in models of monocyte gene expression induced by adhesion to matrix structures by surface integrins [61]. A second signal is then delivered by IL-1β in response to the cellular communication. Thus, regulation of COX-2 expression may exist at both transcriptional and post-transcriptional levels, consisting with the COX-2 enzyme as a highly regulated gene [62]. Unregulation of COX-2 may affect inflammatory response together with interpretations that platelet activation and platelet-leukocyte aggregation are frequently linked with these ailments [63-66].

Integrative pathways of COX-2 protein synthesis are associated with monocytes response to different signals and related to activated platelets which regulate through COX-2 gene in a specialized cellular process. This way of control may evolve for a controlled inflammatory response and here we can discuss the results summarized in Fig. 7f and g, when we blocked the CCR2 expressed on the immune cells (example: Monocytes) using the CCR2 antagonist (CR) in their free and
nanoformulations that lead to lowering of immune cell infiltration from the circulation. Providing AV to CR in their free and nanoformulations significantly inhibited VEGF. Eventually, the accumulation of monocytes in the circulating blood leads to platelet (PLT)-monocyte interaction with the aggregation of the PLT in the form of LPCR (Fig. 7g).

ACKNOWLEDGMENTS

The authors would like to thank the principal investigator Dr. Ahmed A. Abd-Rabou for providing support by the National Research Centre Grant (No: 11010333).

ETHICS

The study protocol followed the guidelines approved by the Ethical Committee of the Medical Research of the National Research Centre (Approval No. 16/281).

AUTHORS’ CONTRIBUTIONS

Abd-Rabou AA contributed in gaining fund, hypothesizing the manuscript idea, practical work, data analysis, manuscript writing, and manuscript reviewing. Ahmed HH contributed in practical work, data analysis, manuscript writing, and manuscript reviewing. Kishita MS contributed in hypothesizing the manuscript idea, practical work, and manuscript reviewing.

CONFLICTS OF INTEREST

The authors report no conflicts of interest.

REFERENCES

1. Rollins BJ. Chemokines. Blood 1997;90:909-28.
2. Deshmale SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res 2009;29:313-26.
3. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham JI, et al. International union of basic and clinical pharmacology. [corrected]. LXXIXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 2014;66:1-79.
4. Charo IF, Myers SJ, Herman A, Franchi C, Connolly AJ, Coughlin SR, et al. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxy-terminal tails. Proc Natl Acad Sci U S A 1994;91:2752-6.
5. Zhang T, Somassandaram B, Beresini K, Caputo L, Gimotty P, Rani P, et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol 2006;36:457-67.
6. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-42.
7. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. J Exp Med 2004;199:47-58.
8. Roth A, von Andrian UH. Chemokines in innate and adaptive host defense: Basic chemokine grammar for immune cells. Immunol Rev 2004;199:47-58.
9. A.O.A.C. Official Methods of Analysis. 16th ed. Washington, DC: Association of Official Analysis; 1995.
10. Banchroft JD, Stevens A, Turner DR. Theory and Practice of Histological Techniques. 4th ed. New York, London, San Francisco, Tokyo: Churchill Livingstone; 1996.
11. Ueda Y, Yang K, Foster SJ, Kondo M, Kelsoe G. Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J Exp Med 2004;199:87-98.
12. Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, Förster R, Sedgwick JD, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000;406:309-14.
13. Serbina NV, Pamer EG. Monocyte emigration from bone marrow and its free counterpart. Asian Pac J Cancer Prev 2017;18:3538-46.
14. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/INOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003;19:59-70.
15. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006;7:311-7.
16. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
17. Hijaz M, Das S, Mert I, Gupta A, Al-Wahab Z, Tobe B, et al. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer. BMC Cancer 2016;16:220.
18. Abd-Rabou AA, Bharali DJ, Mousa SA. Taribavirin and 5-fluorouracil-loaded pegylated-lipid nanoparticle synthesis, p38 docking, and antitumorigenic effects on MCF-7 breast cancer. Pharm Res 2018;35:76.
19. Abd-Rabou AA, Ahmed HH. CS-PeG decorated PLGA nano-prototype for delivery of bioactive compounds: A novel approach for induction of hepg2 cell line. Adv Med Sci 2017;62:357-67.
20. Abd-Rabou AA, Abdalla AM, Ali NA, Zoheir KM. Morinda oleifera root induces basic chemokine receptor mRNA more effectively than leave nanocomposites and its free counterpart. Asian Pac J Cancer Prev 2018;17:2141-9.
21. Shahly AB, Abd-Rabou AA, Ahmed HH. Nano-Se cross talks with nano-DOX/FU to selectively hack hepatic cancer cells and spare normal cells healthy: A mechanism-based study. J Appl Pharm Sci 2017;7:3-12.
22. Auerbuch V, Brockstedt DG, Meyer-Morse N, O’Riordan M, Lipp M, Förster R, et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific Pegylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2010;9:1719-29.
23. Panyam J, Labhaswar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329-47.
24. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, Chen X, et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 2011;32:3538-46.
25. A.O.A.C. Official Methods of Analysis. 16th ed. Washington, DC: Association of Official Analysis; 1995.
26.指南 B, Abd-Rabou AA, Ahmed HH. Nano-DOX/FU to selectively hack hepatic cancer cells and spare normal cells healthy: A mechanism-based study. J Appl Pharm Sci 2017;7:3-12.
27. Chae SY, Kim TH, Park CW, Lee S, Lee J, et al. Improved antitumour activity and tumor targeting of NH(2)-terminal-specific Pegylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2010;9:1719-29.
28. A.O.A.C. Official Methods of Analysis. 16th ed. Washington, DC: Association of Official Analysis; 1995.
29. Abd-Rabou AA, Abdalla AM, Ali NA, Zoheir KM. Morinda oleifera root induces basic chemokine receptor mRNA more effectively than leave nanocomposites and its free counterpart. Asian Pac J Cancer Prev 2018;17:2141-9.
30. Shahly AB, Abd-Rabou AA, Ahmed HH. Nano-Se cross talks with nano-DOX/FU to selectively hack hepatic cancer cells and spare normal cells healthy: A mechanism-based study. J Appl Pharm Sci 2017;7:3-12.
31. Panyam J, Labhaswar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329-47.
32. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, Chen X, et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 2011;32:3538-46.
evaluation of nanoliposomes-encapsulated bevacizumab in vitro, Formation of platelet-leukocyte aggregates in inflammatory

Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA, Handel TM, Domaille PJ. Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 1996;35:6569-84.

Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: Objective tumor response is associated with symptoms in patients with metastatic breast cancer. J Clin Oncol 2000;18:2395-405.

Umano M, Uchi K, Uriada T, Murayama S, Azuma H, Shinohara A, et al. Tumor accumulation of e-poly-lysines-based polyamides conjugated with boron clusters. Appl Radiat Isot 2011;69:1765-7.

Tahara K, Furukawa S, Yamanoto H, Kawashima Y. Hybrid-modified poly(D,L-lactide-co-glycolide) nanospheres for a novel cellular drug delivery system. Int J Pharm 2010;329:311-3.

Li F, Hurley B, Liu Y, Leonard B, Griffith M. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 2012;6:54-8.

Ahrishi M, Zarei-Gharavati S, Soroush D, Rouhiakhsh M, Jafarri MR, Malaeekeh-Nikouei B, et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 2009;29:699-703.

Hao Y, Patel A, Liu W, Krishna R, Sabates NR, Mitra AK. Preparation and Characterization of Bevacizumab (Avastin) Nanoparticles for the Treatment of Age Related Macular Degeneration. Los Angeles, California, U.S.A: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition; 2009. Available from: http://www.aapsj.org/abstracts/AM_2009/AAPS2009-002539.PDF.

Cao X, Schoch MS. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials 1999;20:329-39.

Malhotra M, Lane C, Tomaro-Duchesneau C, Saha S, Prakash S, Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TN, Proudfoot A, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998;188:157-67.

Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83.

Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaide N, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 2003;22:773-8.

Sato K, Kuratsu J, Takeshima H, Yoshimura T, Ushio Y. Expression of monocyte chemoattractant protein-1 in meningioma. J Neurosurg 1995;82:874-8.

Vaikovic T, Dobrilic F, Melato M, Sasso F, Rizzardi C, Onjic N, et al. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Vircsows Arch 2002;440:583-8.

Dixon DA, Tolley ND, Bemis-Standoli K, Martinez ML, Weyrich AS, Morrow JD, et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 2008;116:2727-38.

Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996;97:1525-34.

Juliano RL, Haskill S. Signal transduction from the extracellular matrix. J Cell Biol 1993;120:577-85.

FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2002;3:879-89.

Haskill S. Angiogenesis: Objective tumor response is associated with symptoms in patients with metastatic breast cancer. J Clin Oncol 2000;18:2395-405.

Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BI, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease? J Am Coll Cardiol 1996;28:345-53.

Irving PM, Macey MG, Shah U, Webb L, Langmead L, Rampton DS, et al. Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis 2004;10:361-72.

Miladiyah I, Jumina J, Haryana SM, Mustofa M. In silico molecular docking of xanthone derivatives as cyclooxygenase-2 inhibitor agents. Int J Pharm Pharm Sci 2017;9:79-88.

Chaithanya KK, Gopalakrishnan VK, Hagos Z, Rao DG. Mesuaferrin a-bioactive flavonoid isolated from the bark of Mesua ferrea l. against phospholipase a2, cyclooxygenase and lipoxigenase: An in vitro, in vivo and in silico approach. Int J Pharm Pharm Sci 2018;10:102.